Molly Jenkins, Director of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), has raised concerns about the accountability of hospitals in the 340B Drug Pricing Program.
National Consumers League announced the results of a new Morning Consult national poll showing strong public support for comprehensive reforms to the 340B Drug Pricing Program.
Joe Grogan, former Director of the Domestic Policy Council under the Trump Administration, has expressed concerns about the misuse of the 340B drug discount program by nonprofit hospitals and pharmacy benefit managers.
Pharmacists United for Truth and Transparency said pharmacy benefit managers (PBMs) are the primary driver of high drug prices in the U.S., highlighting how PBMs profit from negotiated savings.
U.S. Sen. Bill Cassidy (R-La.) said that Congress needs to reform the federal 340b federal drug discount program, after he released the results of an investigation showing ‘transparency and oversight concerns’ with the program.
Kasia Mulligan, a spokesperson for the Patients Come First advocacy group, said that the 340B drug discount program lacks transparency and has been exploited by hospitals, preventing savings from reaching low-income patients. She made this statement in the DC Journal.
Sally Greenberg, CEO of the National Consumers League (NCL), said the federal 340B drug discount program, initially intended to assist low-income patients, has become a “financial bonanza for non-profit hospitals.”
John O’Brien, the president and CEO of the National Pharmaceutical Council (NPC), said reforms to the federal 340b drug discount program are needed to rein in the “growth in profiteering” from the program.
A former official with the U.S. Department of Health and Human Services (HHS) said the federal 340b drug discount program is a reminder of “abuse and waste” that exists in Washington, D.C.